Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
dc.contributor.author | MacVicar, Gary R. | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.date.accessioned | 2006-09-11T18:23:31Z | |
dc.date.available | 2006-09-11T18:23:31Z | |
dc.date.issued | 2005-11 | en_US |
dc.identifier.citation | MacVicar, Gary R.; Hussain, Maha; (2005). "Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes." Cancer Chemotherapy and Pharmacology 56(7): 69-77. <http://hdl.handle.net/2027.42/46931> | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.issn | 1432-0843 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46931 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16273364&dopt=citation | en_US |
dc.description.abstract | Prostate cancer remains a significant health concern for men in the USA as it is a leading cancer diagnosis and a cause of death. With the use of prostate-specific antigen or screening, a stage migration has occurred with an increase in the number of men diagnosed with early-stage disease. The optimal primary management of these men is evolving, but despite adequate local treatment a significant percentage will develop either biochemical or clinical evidence of recurrent disease. Several criteria for risk stratification have been developed, thus, improving the ability to identify a high-risk population. Small studies have been reported demonstrating the feasibility of neoadjuvant or adjuvant chemotherapy in conjunction with either radiation or radical prostatectomy in this high-risk population, and large phase III studies are ongoing. With the advent of life-prolonging chemotherapy in the hormone-refractory setting, attention must now also be given to early-stage disease so as to develop multi-modality approaches with the hope of increasing survival and ultimately providing a cure. | en_US |
dc.format.extent | 223257 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Prostate Cancer | en_US |
dc.subject.other | Chemotherapy | en_US |
dc.subject.other | Neoadjuvant Therapy | en_US |
dc.subject.other | Adjuvant Therapy | en_US |
dc.subject.other | Multimodality Therapy | en_US |
dc.title | Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, 7314 CCGC, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-0946, USA, | en_US |
dc.contributor.affiliationother | Division of Hematology/Oncology, Northwestern University, Chicago, IL, 60611, USA, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 16273364 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46931/1/280_2005_Article_103.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00280-005-0103-7 | en_US |
dc.identifier.source | Cancer Chemotherapy and Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.